DERMATOLOGICAL TOXICITY OF CANCER PATIENTS RECEIVING SMALL MOLECULE EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS – A PROSPECTIVE OBSERVATIONAL STUDY
DOI:
https://doi.org/10.22159/ajpcr.2024.v17i1.48823Keywords:
Epidermal growth factor receptor, Papulopustules, Paronychia, Regulatory abnormalities of hair growth, Itching and dryness due to EGFR inhibitors, National Cancer Institute-Common Terminology Criteria for Adverse EventsAbstract
Objectives: The objectives of the study are as follows: (1) To study the incidence of dermatological toxicity in patients receiving small molecule epidermal growth factor receptor inhibitors. (2) To assess the severity of dermatological toxicity.
Methods: This prospective observational study of 66 cancer patients carried out in the Department of Radiotherapy, Government Medical College, Thiruvananthapuram. Patients with histopathological evidence of cancer receiving small molecule epidermal growth factor receptor inhibitors and satisfying inclusion criteria were taken up in the study after obtaining written informed consent. History and clinical examination before initiation of treatment done. Data regarding the occurrence of developing dermatological toxicities were obtained by questioning for symptoms and with the help of structured proforma. Severities of dermatological toxicities were assessed, and toxicity grading was done.
Results: Sixty-six cancer patients enrolled in the study. The mean age of the patients was 62.4 years. The prevalence was higher in men (53%). Sixty-three patients (95.5%) developed at least one dermatological toxicity. The most common dermatological toxicity observed was papulopustular rash (68.2%), followed by xerosis (66.7%) and pruritus (59.1%).
Conclusion: The present study has thus determined the incidence and severity of dermatological toxicity of cancer patients receiving small molecule epidermal growth factor receptor inhibitors.
Downloads
References
Abdullah SE, Haigentz M, Piperdi B. Dermatologic toxicities from monoclonal antibodies and tyrosine kinase inhibitors against EGFR. Pathophysiology and management. Chemother Res Pract 2012;2012:351210. doi: 10.1155/2012/351210, PMID 22997576
Yarden Y, Sliwkowski MX. Untangling the ErbBsignaling network. Nat Rev Mol Cell Biol 2001;2:127-37. doi: 10.1038/35052073, PMID 11252954
Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 2001;13:506-13. doi: 10.1097/00001622-200111000-00014, PMID 11673692
Madke B, Gole P, Kumar P, Khopkar U. Dermatological side effects of epidermal growth factor receptor inhibitors: ”PRIDE” complex. Indian J Dermatol 2014;59:271-4. doi: 10.4103/0019-5154.131398, PMID 24891659
NCI Common Terminology Criteria for Adverse Events v4.03 (CTCAE). Available from: https://ctcae_4.03_2010-06-14_ quickreference_8.5x11.pdf
Roé E, Muret MP, Marcuello E, Capdevila J, Pallarés C, Alomar A. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: A prospective study of 30 patients. J Am Acad Dermatol 2006;55:429-37. doi: 10.1016/j.jaad.2006.04.062
Yoshida T, Yamada K, Azuma K, Kawahara A, Abe H, Hattori S, et al. Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: A retrospective analysis. Med Oncol. 2013;30:349. doi: 10.1007/s12032-012-0349-y, PMID 23263831.
Chu CY, Chen KY, Wen-Cheng Chang J, Wei YF, Lee CH, Wang WM. Taiwanese dermatological association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities. J Formos Med Assoc 2017;116:413-23. doi: 10.1016/j.jfma.2017.03.001, PMID 28351555
Chanprapaph K, Pongcharoen P, Vachiramon V. Cutaneous adverse events of epidermal growth factor receptor inhibitors: A retrospective review of 99 cases. Indian J Dermatol Venereol Leprol 2015;81:547. doi: 10.4103/0378-6323.157448, PMID 25994883
Eaby-Sandy B, Grande C, Viale PH. Dermatologic toxicities in epidermal growth factor receptor and multikinase inhibitors. J Adv Pract Oncol 2012;3:138-50. doi: 10.6004/jadpro.2012.3.3.2, PMID 25031940
Califano R, Tariq N, Compton S, Fitzgerald DA, Harwood CA, Lal R, et al. Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK. Drugs 2015;75:1335-48. doi: 10.1007/s40265-015-0434-6, PMID 26187773
Published
How to Cite
Issue
Section
Copyright (c) 2023 ANAND RG, MINU, VISHNU R, ANU ELINE MATHEW
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
